[New prospects in the treatment of diabetic retinopathy. Current situation and pharmacological developments].
Lagrèze
W A
WA
Neuroophthalmologie und Schielbehandlung, Universitäts-Augenklinik, Freiburg. mail@lagreze.de
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D017321:Clinical Trials, Phase I as Topic; D003922:Diabetes Mellitus, Type 1 / Q000150:complications*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications*; D003930:Diabetic Retinopathy / Q000175:diagnosis / Q000188:drug therapy / Q000209:etiology / Q000601:surgery / Q000628:therapy*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D016023:Integrins / Q000037:antagonists & inhibitors; D017075:Laser Coagulation; D008297:Male; D008301:Maleimides / Q000627:therapeutic use; D008403:Mass Screening; D061965:Matrix Metalloproteinase Inhibitors; D008875:Middle Aged; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000175:diagnosis; D011493:Protein Kinase C / Q000037:antagonists & inhibitors; D012307:Risk Factors; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
D004791:Enzyme Inhibitors; D007211:Indoles; D016023:Integrins; D008301:Maleimides; D061965:Matrix Metalloproteinase Inhibitors; D042461:Vascular Endothelial Growth Factor A; C099154:ruboxistaurin; D011493:Protein Kinase C